{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:16:29Z","timestamp":1793823389804,"version":"4.6.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T00:00:00Z","timestamp":1678060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T00:00:00Z","timestamp":1678060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100011772","name":"Novartis Farmac\u00e9utica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011772","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Peptide receptor radionuclide therapy (PRRT) is one of the most promising therapeutic strategies in neuroendocrine neoplasms (NENs). Nevertheless, its role in certain tumor sites remains unclear. This study sought to elucidate the efficacy and safety of [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-DOTATATE in NENs with different locations and evaluate the effect of the tumor origin, bearing in mind other prognostic variables. Advanced NENs overexpressing somatostatin receptors (SSTRs) on functional imaging, of any grade or location, treated at 24 centers were enrolled. The protocol consisted of four cycles of\n                      <jats:sup>177<\/jats:sup>\n                      Lu-DOTATATE 7.4 GBq iv every 8\u00a0weeks (NCT04949282).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The sample comprised 522 subjects with pancreatic (35%), midgut (28%), bronchopulmonary (11%), pheochromocytoma\/ paraganglioma (PPGL) (6%), other gastroenteropancreatic (GEP) (11%), and other non-gastroenteropancreatic (NGEP) (9%) NENs. The best RECIST 1.1 responses were complete response, 0.7%; partial response, 33.2%; stable disease, 52.1%; and tumor progression, 14%, with activity conditioned by the tumor subtype, but with benefit in all strata. Median progression-free survival (PFS) was 31.3\u00a0months (95% CI, 25.7\u2013not reached [NR]) in midgut, 30.6\u00a0months (14.4-NR) in PPGL, 24.3\u00a0months (18.0-NR) in other GEP, 20.5\u00a0months (11.8-NR) in other NGEP, 19.8\u00a0months (16.8\u201328.1) in pancreatic, and 17.6\u00a0months (14.4\u201333.1) in bronchopulmonary NENs. [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-DOTATATE exhibited scant severe toxicity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      This study confirms the efficacy and safety of [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-DOTATATE in a wide range of SSTR-expressing NENs, regardless of location, with clinical benefit and superimposable survival outcomes between pNENs and other GEP and NGEP tumor subtypes different from midgut NENs.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-023-06166-8","type":"journal-article","created":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T03:03:04Z","timestamp":1678071784000},"page":"2486-2500","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["Efficacy of [177Lu]Lu-DOTATATE in metastatic neuroendocrine neoplasms of different locations: data from the SEPTRALU study"],"prefix":"10.1007","volume":"50","author":[{"given":"Mercedes","family":"Mitjavila","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Jimenez-Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Bell\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Pubul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Percovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amparo","family":"Garcia-Burillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Hernando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Arbizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Rode\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Estorch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bel\u00e9n","family":"Llana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maribel","family":"Castell\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Garc\u00eda-Ca\u00f1amaque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Gajate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Carmen","family":"Riesco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Bego\u00f1a","family":"Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Balaguer-Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Custodio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juana Mar\u00eda","family":"Cano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Repetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Garcia-Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Angustias","family":"Muros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Luis","family":"Vercher-Conejero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1930-9660","authenticated-orcid":false,"given":"Alberto","family":"Carmona-Bayonas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,6]]},"reference":[{"key":"6166_CR1","doi-asserted-by":"publisher","first-page":"895","DOI":"10.2217\/fon.11.66","volume":"7","author":"J Hasskarl","year":"2011","unstructured":"Hasskarl J, Kaufmann M, Schmid HA. Somatostatin receptors in non-neuroendocrine malignancies: the potential role of somatostatin analogs in solid tumors. Futur Oncol Futur Med. 2011;7:895\u2013913.","journal-title":"Futur Oncol Futur Med"},{"key":"6166_CR2","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s11912-017-0633-2","volume":"19","author":"A Carmona-Bayonas","year":"2017","unstructured":"Carmona-Bayonas A, Jim\u00e9nez-Fonseca P, Custodio A, Grande E, Capdevila J, L\u00f3pez C, et al. Optimizing somatostatin analog use in well or moderately differentiated gastroenteropancreatic neuroendocrine tumors. Curr Oncol Rep. 2017;19:72.","journal-title":"Curr Oncol Rep"},{"key":"6166_CR3","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ejca.2021.01.008","volume":"146","author":"V Ambrosini","year":"2021","unstructured":"Ambrosini V, Kunikowska J, Baudin E, Bodei L, Bouvier C, Capdevila J, et al. Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. Eur J Cancer Elsevier. 2021;146:56\u201373.","journal-title":"Eur J Cancer Elsevier"},{"key":"6166_CR4","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.neo.2017.09.002","volume":"19","author":"B Oronsky","year":"2017","unstructured":"Oronsky B, Ma PC, Morgensztern D, Carter CA. Nothing but NET: a review of neuroendocrine tumors and carcinomas. Neoplasia Elsevier. 2017;19:991\u20131002.","journal-title":"Neoplasia Elsevier"},{"key":"6166_CR5","doi-asserted-by":"crossref","unstructured":"Garcia-Carbonero R, Garcia-Figueiras R, Carmona-Bayonas A, Sevilla I, Teule A, Quindos M, et al. Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in development. Cancer Metastasis Rev. 2015;34.","DOI":"10.1007\/s10555-015-9598-5"},{"key":"6166_CR6","doi-asserted-by":"crossref","unstructured":"Camus B, Cottereau A-S, Palmieri L-J, Dermine S, Tenenbaum F, Brezault C, et al. Indications of peptide receptor radionuclide therapy (PRRT) in gastroenteropancreatic and pulmonary neuroendocrine tumors: an updated review. J Clin Med. MDPI; 2021;10:1267.","DOI":"10.3390\/jcm10061267"},{"key":"6166_CR7","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/S0140-6736(89)91258-0","volume":"333","author":"EP Krenning","year":"1989","unstructured":"Krenning EP, Breeman WAP, Kooij PPM, Lameris JS, Bakker WH, Koper JW, et al. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet Elsevier. 1989;333:242\u20134.","journal-title":"Lancet. Elsevier"},{"key":"6166_CR8","doi-asserted-by":"publisher","unstructured":"Jimenez-Fonseca P, Carmona-Bayonas A, Lamarca A, Barriuso J, Casta\u00f1o \u00c1, Benavent M, et al. External validity of somatostatin analogues trials in advanced neuroendocrine neoplasms: the GETNE-TRASGU study. Neuroendocrinology [Internet]. 2021; Available from:https:\/\/www.karger.com, https:\/\/doi.org\/10.1159\/000514808","DOI":"10.1159\/000514808"},{"key":"6166_CR9","doi-asserted-by":"publisher","first-page":"R417","DOI":"10.1530\/ERC-20-0122","volume":"27","author":"A Kasajima","year":"2020","unstructured":"Kasajima A, Kl\u00f6ppel G. Neuroendocrine neoplasms of lung, pancreas and gut: a morphology-based comparison. Endocr Relat Cancer Bioscientifica Ltd. 2020;27:R417-32.","journal-title":"Endocr Relat Cancer Bioscientifica Ltd"},{"key":"#cr-split#-6166_CR10.1","doi-asserted-by":"crossref","unstructured":"Carmona-Bayonas A, Jim\u00e9nez-Fonseca P, Lamarca \u00c1, Barriuso J, Casta\u00f1o \u00c1, Benavent M, et al. Prediction of progression-free survival in patients with advanced, well-differentiated, neuroendocrine tumors being treated with a somatostatin analog: The GETNE-TRASGU Study. J. Clin. Oncol. [Internet]. 2019\/08\/07. American Society of Clinical Oncology","DOI":"10.1200\/JCO.19.00980"},{"key":"#cr-split#-6166_CR10.2","unstructured":"2019;37:2571-80. Available from:\u00a0https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31390276. Accessed 2 Mar 2023"},{"key":"6166_CR11","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1038\/s41379-018-0110-y","volume":"31","author":"G Rindi","year":"2018","unstructured":"Rindi G, Klimstra DS, Abedi-Ardekani B, Asa SL, Bosman FT, Brambilla E, et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol Nature Publishing Group. 2018;31:1770\u201386.","journal-title":"Mod Pathol Nature Publishing Group"},{"key":"6166_CR12","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1002\/cncr.11105","volume":"97","author":"IM Modlin","year":"2003","unstructured":"Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97:934\u201359.","journal-title":"Cancer."},{"key":"6166_CR13","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med Mass Medical Soc. 2017;376:125\u201335.","journal-title":"N Engl J Med Mass Medical Soc"},{"key":"6166_CR14","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","volume":"22","author":"JR Strosberg","year":"2021","unstructured":"Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, et al. 177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol Elsevier. 2021;22:1752\u201363.","journal-title":"Lancet Oncol Elsevier"},{"key":"6166_CR15","doi-asserted-by":"publisher","first-page":"4617","DOI":"10.1158\/1078-0432.CCR-16-2743","volume":"23","author":"T Brabander","year":"2017","unstructured":"Brabander T, Van der Zwan WA, Teunissen JJM, Kam BLR, Feelders RA, de Herder WW, et al. Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0, Tyr3] octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine TumorsEfficacy, Survival, and Toxicity after 177Lu-DOTATATE. Clin Cancer Res AACR. 2017;23:4617\u201324.","journal-title":"Clin Cancer Res AACR"},{"key":"6166_CR16","doi-asserted-by":"crossref","unstructured":"Pavlakis N, Ransom DT, Wyld D, Sjoquist KM, Wilson K, Gebski V, et al. Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) and capecitabine plus temozolomide (CAPTEM) for pancreas and midgut neuroendocrine tumours (pNETS, mNETS)\u2014Final results. American Society of Clinical Oncology; 2022.","DOI":"10.1200\/JCO.2022.40.16_suppl.4122"},{"key":"6166_CR17","doi-asserted-by":"crossref","unstructured":"Garske-Rom\u00e1n U, Sandstr\u00f6m M, Fr\u00f6ss Baron K, Lundin L, Hellman P, Welin S, et al. Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity. Eur. J. Nucl. Med. Mol. Imaging. Springer; 2018;45:970\u201388.","DOI":"10.1007\/s00259-018-3945-z"},{"key":"6166_CR18","doi-asserted-by":"publisher","first-page":"126","DOI":"10.2174\/1874471012666190201164132","volume":"12","author":"S Alsadik","year":"2019","unstructured":"Alsadik S, Yusuf S, Al-Nahhas A. Peptide receptor radionuclide therapy for pancreatic neuroendocrine tumours. Curr Radiopharm Bentham Sci Publishers. 2019;12:126\u201334.","journal-title":"Curr Radiopharm Bentham Sci Publishers"},{"key":"6166_CR19","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s00259-013-2677-3","volume":"41","author":"S Ezziddin","year":"2014","unstructured":"Ezziddin S, Khalaf F, Vanezi M, Haslerud T, Mayer K, Al Zreiqat A, et al. Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1\/2 pancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging Springer. 2014;41:925\u201333.","journal-title":"Eur J Nucl Med Mol Imaging Springer"},{"key":"6166_CR20","first-page":"16932","volume":"9","author":"RP Baum","year":"2018","unstructured":"Baum RP, Kulkarni HR, Singh A, Kaemmerer D, Mueller D, Prasad V, et al. Results and adverse events of personalized peptide receptor radionuclide therapy with 90Yttrium and 177Lutetium in 1048 patients with neuroendocrine neoplasms. Oncotarget Impact Journals LLC. 2018;9:16932.","journal-title":"Oncotarget Impact Journals LLC"},{"key":"6166_CR21","first-page":"e328","volume":"27","author":"J Capdevila","year":"2022","unstructured":"Capdevila J, Grande E, Garc\u00eda-Carbonero R, Sim\u00f3 M, del Olmo-Garc\u00eda MI, Jim\u00e9nez-Fonseca P, et al. Position statement on the diagnosis, treatment, and response evaluation to systemic therapies of advanced neuroendocrine tumors, with a special focus on radioligand therapy. Oncologist Oxford University Press US. 2022;27:e328-39.","journal-title":"Oncologist. Oxford University Press US"},{"key":"6166_CR22","first-page":"471","volume":"68","author":"M Cives","year":"2018","unstructured":"Cives M, Strosberg JR. Gastroenteropancreatic neuroendocrine tumors CA. Cancer J Clin Wiley Online Library. 2018;68:471\u201387.","journal-title":"Cancer J Clin Wiley Online Library"},{"key":"6166_CR23","doi-asserted-by":"crossref","unstructured":"Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J. Nucl. Med. Division of Nuclear Medicine, Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287-0817, USA. rwahl@jhmi.edu; 2009;50 Suppl 1:122S-50S.","DOI":"10.2967\/jnumed.108.057307"},{"key":"6166_CR24","first-page":"3099","volume":"72","author":"E Bajetta","year":"1993","unstructured":"Bajetta E, Zilembo N, Di Bartolomeo M, Di Leo A, Pilotti S, Bochicchio AM, et al. Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon-alpha-2a: A study by the Italian trials in Medical Oncology Group. Cancer Wiley Online Library. 1993;72:3099\u2013105.","journal-title":"Cancer Wiley Online Library"},{"key":"6166_CR25","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1093\/aje\/kws412","volume":"177","author":"D Westreich","year":"2013","unstructured":"Westreich D, Greenland S. The table 2 fallacy: presenting and interpreting confounder and modifier coefficients. Am J Epidemiol Oxford University Press. 2013;177:292\u20138.","journal-title":"Am. J. Epidemiol. Oxford University Press"},{"key":"6166_CR26","doi-asserted-by":"crossref","unstructured":"Morris TP, White IR, Royston P. Tuning multiple imputation by predictive mean matching and local residual draws. BMC Med Res Methodol. BioMed Central; 2014;14:75.","DOI":"10.1186\/1471-2288-14-75"},{"key":"6166_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-19425-7","volume-title":"Regression modeling strategies: with applications to linear models, logistic and ordinal regression, and survival analysis","author":"F Harrell","year":"2015","unstructured":"Harrell F. Regression modeling strategies: with applications to linear models, logistic and ordinal regression, and survival analysis. 2nd ed. New York: Springer; 2015.","edition":"2"},{"key":"6166_CR28","doi-asserted-by":"crossref","unstructured":"E. Shemyakin A, Youn H. Copula models of joint last survivor analysis. Appl. Stoch. Model. Bus. Ind. Wiley Online Library; 2006;22:211\u201324.","DOI":"10.1002\/asmb.629"},{"key":"6166_CR29","doi-asserted-by":"crossref","unstructured":"Niederle B, Pape U-F, Costa F, Gross D, Kelestimur F, Knigge U, et al. ENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum. Neuroendocrinology [Internet]. 2016;103:125\u201338. Available from:\u00a0http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26758972. Accessed 2 Mar 2023","DOI":"10.1159\/000443170"},{"key":"6166_CR30","doi-asserted-by":"crossref","unstructured":"Vinik AI, Woltering EA, Warner RRP, Caplin M, O\u2019Dorisio TM, Wiseman GA, et al. NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas [Internet]. 2010 [cited 2015 Dec 25];39:713\u201334. Available from:\u00a0http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20664471. Accessed 2 Mar 2023","DOI":"10.1097\/MPA.0b013e3181ebaffd"},{"key":"6166_CR31","doi-asserted-by":"crossref","unstructured":"Baudin E, Walter TA, Beron A, Smith D, Hadoux J, Lachachi C, et al. 887O First multicentric randomized phase II trial investigating the antitumor efficacy of peptide receptor radionucleide therapy with 177Lutetium-Octreotate (OCLU) in unresectable progressive neuroendocrine pancreatic tumor: Results of the OCLURANDOM tria. Ann. Oncol. Elsevier; 2022;33:S954.","DOI":"10.1016\/j.annonc.2022.07.1013"},{"key":"6166_CR32","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ejca.2016.01.009","volume":"58","author":"D H\u00f6rsch","year":"2016","unstructured":"H\u00f6rsch D, Ezziddin S, Haug A, Gratz KF, Dunkelmann S, Miederer M, et al. Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany: a multi-institutional registry study with prospective follow-up. Eur J Cancer Elsevier. 2016;58:41\u201351.","journal-title":"Eur J Cancer Elsevier"},{"key":"6166_CR33","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1007\/s00259-015-3262-8","volume":"43","author":"A Ianniello","year":"2016","unstructured":"Ianniello A, Sansovini M, Severi S, Nicolini S, Grana CM, Massri K, et al. Peptide receptor radionuclide therapy with 177Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and 18F-FDG PET. Eur J Nucl Med Mol Imaging Springer. 2016;43:1040\u20136.","journal-title":"Eur J Nucl Med Mol Imaging Springer"},{"key":"6166_CR34","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00259-015-3190-7","volume":"43","author":"A Mariniello","year":"2016","unstructured":"Mariniello A, Bodei L, Tinelli C, Baio SM, Gilardi L, Colandrea M, et al. Long-term results of PRRT in advanced bronchopulmonary carcinoid. Eur J Nucl Med Mol Imaging Springer. 2016;43:441\u201352.","journal-title":"Eur J Nucl Med Mol Imaging Springer"},{"key":"6166_CR35","doi-asserted-by":"publisher","first-page":"218","DOI":"10.2967\/jnumed.120.260760","volume":"63","author":"L Zidan","year":"2022","unstructured":"Zidan L, Iravani A, Oleinikov K, Ben-Haim S, Gross DJ, Meirovitz A, et al. Efficacy and safety of 177Lu-DOTATATE in lung neuroendocrine tumors: a bicenter study. J Nucl Med Soc Nuclear Med. 2022;63:218\u201325.","journal-title":"J Nucl Med Soc Nuclear Med"},{"key":"6166_CR36","first-page":"2636","volume":"11","author":"LE Lim","year":"2020","unstructured":"Lim LE, Chan DL, Thomas D, Du Y, Tincknell G, Kuchel A, et al. Australian experience of peptide receptor radionuclide therapy in lung neuroendocrine tumours. Oncotarget Impact Journals LLC. 2020;11:2636.","journal-title":"Oncotarget Impact Journals LLC"},{"key":"6166_CR37","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.lungcan.2020.10.005","volume":"150","author":"E Mirvis","year":"2020","unstructured":"Mirvis E, Toumpanakis C, Mandair D, Gnanasegaran G, Caplin M, Navalkissoor S. Efficacy and tolerability of peptide receptor radionuclide therapy (PRRT) in advanced metastatic bronchial neuroendocrine tumours (NETs). Lung Cancer Elsevier. 2020;150:70\u20135.","journal-title":"Lung Cancer Elsevier"},{"key":"6166_CR38","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1097\/RLU.0000000000001639","volume":"42","author":"RV Parghane","year":"2017","unstructured":"Parghane RV, Talole S, Prabhash K, Basu S. Clinical response profile of metastatic\/advanced pulmonary neuroendocrine tumors to peptide receptor radionuclide therapy with 177Lu-DOTATATE. Clin Nucl Med LWW. 2017;42:428\u201335.","journal-title":"Clin Nucl Med LWW"},{"key":"6166_CR39","doi-asserted-by":"publisher","first-page":"952","DOI":"10.3390\/jcm8070952","volume":"8","author":"A Kolasinska-\u0106wik\u0142a","year":"2019","unstructured":"Kolasinska-\u0106wik\u0142a A, P\u0119czkowska M, \u0106wik\u0142a JB, Micha\u0142owska I, Pa\u0142ucki JM, Bodei L, et al. A clinical efficacy of PRRT in patients with advanced, nonresectable, paraganglioma-pheochromocytoma, related to SDHx gene mutation. J Clin Med MDPI. 2019;8:952.","journal-title":"J Clin Med MDPI"},{"key":"6166_CR40","first-page":"100171","volume":"6","author":"S Severi","year":"2021","unstructured":"Severi S, Bongiovanni A, Ferrara M, Nicolini S, Di Mauro F, Sansovini M, et al. Peptide receptor radionuclide therapy in patients with metastatic progressive pheochromocytoma and paraganglioma: long-term toxicity, efficacy and prognostic biomarker data of phase II clinical trials ESMO open. Elsevier. 2021;6:100171.","journal-title":"Elsevier"},{"key":"6166_CR41","doi-asserted-by":"crossref","unstructured":"Satapathy S, Mittal BR, Bhansali A. \u201cPeptide receptor radionuclide therapy in the management of advanced pheochromocytoma and paraganglioma: a systematic review and meta-analysis.\u201d Clin. Endocrinol. (Oxf). [Internet]. Department of Nuclear Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India.; 2019;91:718\u201327. Available from:\u00a0http:\/\/europepmc.org\/abstract\/MED\/31569282. Accessed 2 Mar 2023","DOI":"10.1111\/cen.14106"},{"key":"6166_CR42","doi-asserted-by":"crossref","unstructured":"Nastos K, Cheung VTF, Toumpanakis C, Navalkissoor S, Quigley A-M, Caplin M, et al. Peptide receptor radionuclide treatment and (131)I-MIBG in the management of patients with metastatic\/progressive phaeochromocytomas and paragangliomas. J. Surg. Oncol. [Internet]. ENETS Centre of Excellence Neuroendocrine Tumour Unit, Royal Free London NHS Foundation Trust, London, UK.; 2017;115:425\u201334. Available from: http:\/\/europepmc.org\/abstract\/MED\/28166370","DOI":"10.1002\/jso.24553"},{"key":"6166_CR43","doi-asserted-by":"crossref","unstructured":"Bodei L, Cremonesi M, Grana CM, Fazio N, Iodice S, Baio SM, et al. Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study. Eur. J. Nucl. Med. Mol. Imaging [Internet]. 2011;38:2125\u201335. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21892623","DOI":"10.1007\/s00259-011-1902-1"},{"key":"6166_CR44","unstructured":"Sabet A, Haug AR, Eiden C, Auernhammer CJ, Simon B, Bartenstein P, et al. Efficacy of peptide receptor radionuclide therapy with 177Lu-octreotate in metastatic pulmonary neuroendocrine tumors: a dual-centre analysis [Internet]. Am. J. Nucl. Med. Mol. Imaging. Department of Nuclear Medicine, Saarland UniversityHomburg, Germany.; 2017. p. 74\u201383. Available from: http:\/\/europepmc.org\/abstract\/MED\/28533939"},{"key":"6166_CR45","doi-asserted-by":"crossref","unstructured":"Imhof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J. Clin. Oncol. [Internet]. Institute of Nuclear Medicine, University Hospital, Petersgraben 4, Basel, Switzerland.; 2011;29:2416\u201323. Available from: http:\/\/europepmc.org\/abstract\/MED\/21555692","DOI":"10.1200\/JCO.2010.33.7873"},{"key":"6166_CR46","doi-asserted-by":"crossref","unstructured":"Pavel ME, Rinke A, Baum RP. COMPETE trial: peptide receptor radionuclide therapy (PRRT) with 177Lu-edotreotide vs everolimus in progressive GEP-NET. Ann. Oncol. Elsevier; 2018;29:viii478.","DOI":"10.1093\/annonc\/mdy293.028"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06166-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-023-06166-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06166-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T01:02:42Z","timestamp":1686186162000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-023-06166-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,6]]},"references-count":47,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["6166"],"URL":"https:\/\/doi.org\/10.1007\/s00259-023-06166-8","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,6]]},"assertion":[{"value":"6 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Research Ethics Committee of the Principality of Asturias (151\/17, November 3, 2017) and by the Spanish Agency of Medicines and Medical Devices (AEMPS) as a post authorization study with prospective follow-up (PAS-PF) (identification code: CSV: DSRZJ6QF1B). All procedures followed were in accordance with the ethical standards of the committee responsible for human experimentation (institutional, local, and national) and with the Helsinki Declaration of 1964 and later versions. Informed consent was obtained from all patients before being included in the study. This study is an observational, non-interventionist trial. This work is original and has not been previously presented elsewhere.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"ACB has received travel grants and participated in advisory boards from Novartis. The other authors declare that they have no conflicts of interest in relation to the scope of this work. This is an academic study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The SEPTRALU registry (SEMNIM-SER-2021-01) is promoted by Spanish Society of Nuclear Medicine and Molecular Imaging (SEMNIM) in collaboration with the Spanish Society of Endocrinology and Nutrition (SEEN).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimers"}}]}}